GlassScriptPhysician profile
Anilkumar Pillai
NPI 1578519658
$63,965.48
in general payments reported to CMS, 2019-2025
45 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $57K · 2021: $940 · 2022: $833 · 2023: $1,256 · 2024: $1,195 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $56,219.00 | 2020 | |
| Novo Nordisk INC | $1,163.39 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $1,018.08 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $742.23 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $647.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $419.03 | 2022-2025 | |
| Astellas Pharma US INC | $319.21 | 2019-2024 | Veozah |
| Pfizer INC. | $315.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $270.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $269.93 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.55 | 2021-2025 | Jardiance, Synjardy |
| Abbvie INC. | $225.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.63 | 2024-2025 | Caplyta |
| Abbott Laboratories | $188.45 | 2021-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $179.83 | 2020-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $146.13 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $119.42 | 2019-2020 | |
| Beta Bionics, INC. | $119.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $110.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $92.27 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.03 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $86.40 | 2023-2025 | Rexulti |
| Axonics, INC. | $79.28 | 2023 | Axonics |
| Indivior INC. | $78.79 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $65.32 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.50 | 2024 | Voquezna |
| Antares Pharma, INC. | $60.67 | 2022-2024 | Xyosted |
| Dexcom, INC. | $55.75 | 2021-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $42.77 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $33.20 | 2021 | |
| Orexo US, INC. | $33.15 | 2019 | |
| Halozyme INC | $30.72 | 2023 | |
| Esperion Therapeutics, INC. | $29.89 | 2025 | Nexletol |
| Titan Pharmaceuticals, INC. | $24.53 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.47 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $15.32 | 2023 | Quviviq |
| Eisai INC. | $14.41 | 2020 | |
| Hikma Pharmaceuticals USA | $13.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.53 | 2022 | |
| Allergan, INC. | $12.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 | |
| Zyla Life Sciences, INC. | $12.16 | 2019 | |
| Genentech USA, INC. | $11.98 | 2021 | |
| Aytu Biopharma, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anilkumar Pillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.